JP7883950B2 - 神経系の状態の処置 - Google Patents

神経系の状態の処置

Info

Publication number
JP7883950B2
JP7883950B2 JP2022524568A JP2022524568A JP7883950B2 JP 7883950 B2 JP7883950 B2 JP 7883950B2 JP 2022524568 A JP2022524568 A JP 2022524568A JP 2022524568 A JP2022524568 A JP 2022524568A JP 7883950 B2 JP7883950 B2 JP 7883950B2
Authority
JP
Japan
Prior art keywords
pnni
pharmaceutical composition
treatment
injury
spinal cord
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554230A5 (cg-RX-API-DMAC7.html
JP2022554230A (ja
Inventor
クウォク ジェシカ
フォスター リチャード
ダンカン ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Publication of JP2022554230A publication Critical patent/JP2022554230A/ja
Publication of JP2022554230A5 publication Critical patent/JP2022554230A5/ja
Application granted granted Critical
Publication of JP7883950B2 publication Critical patent/JP7883950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022524568A 2019-10-25 2020-10-25 神経系の状態の処置 Active JP7883950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926001P 2019-10-25 2019-10-25
US62/926,001 2019-10-25
PCT/EP2020/079979 WO2021078991A1 (en) 2019-10-25 2020-10-25 Treatment of conditions of the nervous system

Publications (3)

Publication Number Publication Date
JP2022554230A JP2022554230A (ja) 2022-12-28
JP2022554230A5 JP2022554230A5 (cg-RX-API-DMAC7.html) 2023-11-06
JP7883950B2 true JP7883950B2 (ja) 2026-07-02

Family

ID=73455660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524568A Active JP7883950B2 (ja) 2019-10-25 2020-10-25 神経系の状態の処置

Country Status (5)

Country Link
US (1) US20220380331A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048257A1 (cg-RX-API-DMAC7.html)
JP (1) JP7883950B2 (cg-RX-API-DMAC7.html)
CN (1) CN115023222A (cg-RX-API-DMAC7.html)
WO (1) WO2021078991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4440571A1 (en) * 2021-11-30 2024-10-09 Evexys Biotech OY Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514438A (ja) 1998-05-08 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チトクロームp450基質としての7−アルコキシクマリン類
JP2008535824A (ja) 2005-03-29 2008-09-04 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体
JP2016530265A (ja) 2013-08-12 2016-09-29 ベナロヤ リサーチ インスティテュート アット バージニア メイソン 免疫調節のための4−メチルウンベリフェロン処置
US20180201640A1 (en) 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103446154A (zh) * 2012-05-29 2013-12-18 中国医学科学院药物研究所 香豆素衍生物在防治脑部重大疾病中的应用
US11278518B2 (en) * 2017-01-13 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514438A (ja) 1998-05-08 2002-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー チトクロームp450基質としての7−アルコキシクマリン類
JP2008535824A (ja) 2005-03-29 2008-09-04 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換アミノアルキルベンゾピラン誘導体およびアミドアルキルベンゾピラン誘導体
JP2016530265A (ja) 2013-08-12 2016-09-29 ベナロヤ リサーチ インスティテュート アット バージニア メイソン 免疫調節のための4−メチルウンベリフェロン処置
US20180201640A1 (en) 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Arch. Pharm. Chem. Life Sci.,2017年,350,e1700076, page 1-17
Br. J. Pharmacol.,2019年09月,176(18),pp.3611-3621,DOI:10.1111/bph.14672
Chem. Med. Chem.,2017年,12(16),pp.1349-1358,DOI:10.1002/cmdc.201700282
ChemistrySelect,2016年,1,pp.2742-2749,DOI:10.1002/slct.201600735
European Journal of Medicinal Chemistry,2018年10月,161,pp.292-309,DOI:10.1016/j.ejmech.2018.10.016

Also Published As

Publication number Publication date
CN115023222A (zh) 2022-09-06
JP2022554230A (ja) 2022-12-28
WO2021078991A1 (en) 2021-04-29
US20220380331A1 (en) 2022-12-01
EP4048257A1 (en) 2022-08-31

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260622

R150 Certificate of patent or registration of utility model

Ref document number: 7883950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150